Glycosylation is an androgen-regulated process essential for prostate cancer cell viability

Munkley, J. et al. (2016) Glycosylation is an androgen-regulated process essential for prostate cancer cell viability. EBioMedicine, 8, pp. 103-116. (doi: 10.1016/j.ebiom.2016.04.018) (PMID:27428423) (PMCID:PMC4919605)

[img]
Preview
Text
121567.pdf - Published Version
Available under License Creative Commons Attribution.

2MB

Abstract

Steroid androgen hormones play a key role in the progression and treatment of prostate cancer, with androgen deprivation therapy being the first-line treatment used to control cancer growth. Here we apply a novel search strategy to identify androgen-regulated cellular pathways that may be clinically important in prostate cancer. Using RNASeq data, we searched for genes that showed reciprocal changes in expression in response to acute androgen stimulation in culture, and androgen deprivation in patients with prostate cancer. Amongst 700 genes displaying reciprocal expression patterns we observed a significant enrichment in the cellular process glycosylation. Of 31 reciprocally-regulated glycosylation enzymes, a set of 8 (GALNT7, ST6GalNAc1, GCNT1, UAP1, PGM3, CSGALNACT1, ST6GAL1 and EDEM3) were significantly up-regulated in clinical prostate carcinoma. Androgen exposure stimulated synthesis of glycan structures downstream of this core set of regulated enzymes including sialyl-Tn (sTn), sialyl LewisX (SLeX), O-GlcNAc and chondroitin sulphate, suggesting androgen regulation of the core set of enzymes controls key steps in glycan synthesis. Expression of each of these enzymes also contributed to prostate cancer cell viability. This study identifies glycosylation as a global target for androgen control, and suggests loss of specific glycosylation enzymes might contribute to tumour regression following androgen depletion therapy.

Item Type:Articles
Additional Information:This work was funded by the Prostate Cancer UK (PG12-34), the J. G. W Patterson Foundation, the Wellcome Trust (grant numbers WT080368MA and WT089225/Z/09/Z), the BBSRC (grants BB/1006923/1 and BB/J007293/1) and the Breast Cancer Now (grant number 2014NovPR355).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Leung, Professor Hing
Authors: Munkley, J., Vodak, D., Livermore, K. E., James, K., Wilson, B. T., Knight, B., Mccullagh, P., Mcgrath, J., Crundwell, M., Harries, L. W., Leung, H. Y., Robson, C. N., Mills, I. G., Rajan, P., and Elliott, D. J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:EBioMedicine
Publisher:Elsevier
ISSN:2352-3964
ISSN (Online):2352-3964
Published Online:20 April 2016
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in EBioMedicine 8:103-116
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record